Leukotrienes as Modifiers of Preclinical Atherosclerosis?
Preclinical atherosclerosis represents a crucial period associated with several pathophysiological reactions in the vascular wall. Failure to diagnose preclinical atherosclerosis at this stage misses a major opportunity to prevent the long-term consequences of this disease. Surrogate biological and...
Main Authors: | Graziano Riccioni, Magnus Bäck |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/2012/490968 |
Similar Items
-
Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives
by: Graziano Riccioni, et al.
Published: (2009-01-01) -
Role of Leukotrienes and Leukotriene Modifiers in Asthma
by: Paolo Montuschi
Published: (2010-06-01) -
Leukotriene Receptors: Crucial Components in Vascular Inflammation
by: Magnus Bäck
Published: (2007-01-01) -
Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea[S]
by: Françoise Stanke-Labesque, et al.
Published: (2012-09-01) -
Leukotriene modifiers in the treatment of asthma in children
by: Michele Miraglia del Giudice, et al.
Published: (2009-10-01)